These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

122 related items for PubMed ID: 27475989

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
    Saar Ray M, Moskovich O, Iosefson O, Fishelson Z.
    J Biol Chem; 2014 May 23; 289(21):15014-22. PubMed ID: 24719326
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
    Hillman Y, Mazkereth N, Farberov L, Shomron N, Fishelson Z.
    J Immunol; 2016 Jun 15; 196(12):5156-65. PubMed ID: 27183614
    [Abstract] [Full Text] [Related]

  • 5. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
    Pilzer D, Fishelson Z.
    Int Immunol; 2005 Sep 15; 17(9):1239-48. PubMed ID: 16091382
    [Abstract] [Full Text] [Related]

  • 6. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.
    Fishelson Z, Kirschfink M.
    Front Immunol; 2019 Sep 15; 10():752. PubMed ID: 31024572
    [Abstract] [Full Text] [Related]

  • 7. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
    Pilzer D, Saar M, Koya K, Fishelson Z.
    Int J Cancer; 2010 Mar 15; 126(6):1428-35. PubMed ID: 19739077
    [Abstract] [Full Text] [Related]

  • 8. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
    Jubran R, Saar-Ray M, Wawruszak A, Ziporen L, Donin N, Bairey O, Fishelson Z.
    Int J Oncol; 2020 Oct 15; 57(4):1013-1026. PubMed ID: 32700755
    [Abstract] [Full Text] [Related]

  • 9. Mortalin (GRP75/HSPA9) Promotes Survival and Proliferation of Thyroid Carcinoma Cells.
    Starenki D, Sosonkina N, Hong SK, Lloyd RV, Park JI.
    Int J Mol Sci; 2019 Apr 26; 20(9):. PubMed ID: 31027376
    [Abstract] [Full Text] [Related]

  • 10. Elevated levels of mitochondrial mortalin and cytosolic HSP70 in blood as risk factors in patients with colorectal cancer.
    Rozenberg P, Kocsis J, Saar M, Prohászka Z, Füst G, Fishelson Z.
    Int J Cancer; 2013 Jul 15; 133(2):514-8. PubMed ID: 23319326
    [Abstract] [Full Text] [Related]

  • 11. Emission of membrane vesicles: roles in complement resistance, immunity and cancer.
    Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z.
    Springer Semin Immunopathol; 2005 Nov 15; 27(3):375-87. PubMed ID: 16189651
    [Abstract] [Full Text] [Related]

  • 12. Mortalin (HSPA9) facilitates BRAF-mutant tumor cell survival by suppressing ANT3-mediated mitochondrial membrane permeability.
    Wu PK, Hong SK, Chen W, Becker AE, Gundry RL, Lin CW, Shao H, Gestwicki JE, Park JI.
    Sci Signal; 2020 Mar 10; 13(622):. PubMed ID: 32156782
    [Abstract] [Full Text] [Related]

  • 13. Caveolin-1 and dynamin-2 are essential for removal of the complement C5b-9 complex via endocytosis.
    Moskovich O, Herzog LO, Ehrlich M, Fishelson Z.
    J Biol Chem; 2012 Jun 08; 287(24):19904-15. PubMed ID: 22528500
    [Abstract] [Full Text] [Related]

  • 14. Mortalin-mediated and ERK-controlled targeting of HIF-1α to mitochondria confers resistance to apoptosis under hypoxia.
    Mylonis I, Kourti M, Samiotaki M, Panayotou G, Simos G.
    J Cell Sci; 2017 Jan 15; 130(2):466-479. PubMed ID: 27909249
    [Abstract] [Full Text] [Related]

  • 15. Mortalin - a multipotent chaperone regulating cellular processes ranging from viral infection to neurodegeneration.
    Flachbartová Z, Kovacech B.
    Acta Virol; 2013 Jan 15; 57(1):3-15. PubMed ID: 23530819
    [Abstract] [Full Text] [Related]

  • 16. Quantification of complement C5b-9 binding to cells by flow cytometry.
    Moskovich O, Fishelson Z.
    Methods Mol Biol; 2014 Jan 15; 1100():103-8. PubMed ID: 24218253
    [Abstract] [Full Text] [Related]

  • 17. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
    Shankaranarayana AH, Meduri B, Pujar GV, Hariharapura RC, Sethu AK, Singh M, Bidye D.
    Future Med Chem; 2023 Nov 15; 15(22):2087-2112. PubMed ID: 37877348
    [Abstract] [Full Text] [Related]

  • 18. Mortalin: present and prospective.
    Kaul SC, Taira K, Pereira-Smith OM, Wadhwa R.
    Exp Gerontol; 2002 Nov 15; 37(10-11):1157-64. PubMed ID: 12470827
    [Abstract] [Full Text] [Related]

  • 19. Elimination of terminal complement complexes in the plasma membrane of nucleated cells: influence of extracellular Ca2+ and association with cellular Ca2+.
    Carney DF, Hammer CH, Shin ML.
    J Immunol; 1986 Jul 01; 137(1):263-70. PubMed ID: 3711667
    [Abstract] [Full Text] [Related]

  • 20. Mortalin (GRP75/HSPA9) upregulation promotes survival and proliferation of medullary thyroid carcinoma cells.
    Starenki D, Hong SK, Lloyd RV, Park JI.
    Oncogene; 2015 Aug 27; 34(35):4624-34. PubMed ID: 25435367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.